UnitedHealthcare Pharmacy
Clinical Pharmacy Programs
Program Number 2024 P 1243-7
Program Prior Authorization/Non-Formulary
Medication Amlodipine/valsartan/hydrochlorothiazide (generic Exforge HCT®*)
P&T Approval Date 3/2018, 3/2019, 3/2020, 6/2021, 6/2022, 10/2023, 10/2024
Effective Date 1/1/2025
1. Background:
The American College of Cardiology/American Heart Association Task Force recommends
combination pills rather than individual components to improve adherence to antihypertensive
therapy. This program allows for coverage of amlodipine/valsartan/hydrochlorothiazide (generic
Exforge HCT*), a triple antihypertensive therapy, for members who have not achieved an
adequate response with the medications taken separately due to lack of adherence.
2. Coverage Criteriaa:
A. Initial Authorization
1. Amlodipine/valsartan/hydrochlorothiazide (generic Exforge HCT*) will be
approved based on both of the following:
a. Patient has a history of a trial resulting in a therapeutic failure (i.e. blood pressure
goal not met), to both of the following taken concomitantly:
i. amlodipine/valsartan (generic Exforge)
ii. hydrochlorothiazide
-AND-
b. Patient is unable to adhere to antihypertensive therapy and prescriber determines
combination therapy would be beneficial.
Authorization will be issued for 12 months.
B. Reauthorization
1. Amlodipine/valsartan/hydrochlorothiazide (generic Exforge HCT*) will be
approved based on the following criterion:
a. Documentation of positive clinical response to therapy
Authorization will be issued for 12 months.
a State mandates may apply. Any federal regulatory requirements and the member specific
benefit plan coverage may also impact coverage criteria. Other policies and utilization
management programs may apply.
© 2024 UnitedHealthcare Services, Inc.
1
*Brand Exforge HCT is typically excluded from coverage.
3. Additional Clinical Rules:
• Notwithstanding Coverage Criteria, UnitedHealthcare may approve initial and re-authorization
based solely on previous claim/medication history, diagnosis codes (ICD-10) and/or claim logic.
Use of automated approval and re-approval processes varies by program and/or therapeutic class.
4. References:
1. Whelton PK, Carey RM, Aronow WS, et al. 2017
ACC/AHA/AAPA/ABC/ACPM/AGS/APhA/ASH/ASPC/NMA/PCNA guideline for the
prevention, detection, evaluation, and management of high blood pressure in adults: a report of
the American College of Cardiology/American Heart Association Task Force on Clinical Practice
Guidelines. Hypertension. 2017
2. Exforge HCT [package insert]. East Hanover, NJ: Novartis Pharmaceuticals Corporation; July
2023.
Program Prior Authorization/Non-Formulary –
Amlodipine/valsartan/hydrochlorothiazide (generic Exforge HCT)
Change Control
3/2018 New program.
3/2019 Annual review. No changes.
3/2020 Annual review. Updated references.
6/2021 Formatting changes. Updated reference.
6/2022 Annual review. Updated reference.
10/2023 Annual review. Updated reference.
10/2024 Annual review. No changes.
© 2024 UnitedHealthcare Services, Inc.
2